LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes.

    Grobler, Corlia / Maphumulo, Siphosethu C / Grobbelaar, L Mireille / Bredenkamp, Jhade C / Laubscher, Gert J / Lourens, Petrus J / Steenkamp, Janami / Kell, Douglas B / Pretorius, Etheresia

    International journal of molecular sciences

    2020  Volume 21, Issue 14

    Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), also known as coronavirus disease 2019 (COVID-19)-induced infection, is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia or ... ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), also known as coronavirus disease 2019 (COVID-19)-induced infection, is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia or hypercoagulation and thrombosis. Thrombotic and bleeding or thrombotic pathologies are significant accompaniments to acute respiratory syndrome and lung complications in COVID-19. Thrombotic events and bleeding often occur in subjects with weak constitutions, multiple risk factors and comorbidities. Of particular interest are the various circulating inflammatory coagulation biomarkers involved directly in clotting, with specific focus on fibrin(ogen), D-dimer, P-selectin and von Willebrand Factor (VWF). Central to the activity of these biomarkers are their receptors and signalling pathways on endothelial cells, platelets and erythrocytes. In this review, we discuss vascular implications of COVID-19 and relate this to circulating biomarker, endothelial, erythrocyte and platelet dysfunction. During the progression of the disease, these markers may either be within healthy levels, upregulated or eventually depleted. Most significant is that patients need to be treated early in the disease progression, when high levels of VWF, P-selectin and fibrinogen are present, with normal or slightly increased levels of D-dimer (however, D-dimer levels will rapidly increase as the disease progresses). Progression to VWF and fibrinogen depletion with high D-dimer levels and even higher P-selectin levels, followed by the cytokine storm, will be indicative of a poor prognosis. We conclude by looking at point-of-care devices and methodologies in COVID-19 management and suggest that a personalized medicine approach should be considered in the treatment of patients.
    MeSH term(s) Betacoronavirus ; Blood Platelets/metabolism ; COVID-19 ; Coronavirus Infections/pathology ; Cytokine Release Syndrome/pathology ; Endothelial Cells/metabolism ; Erythrocytes/metabolism ; Fibrin Fibrinogen Degradation Products/metabolism ; Humans ; P-Selectin/metabolism ; Pandemics ; Pneumonia, Viral/pathology ; Point-of-Care Systems ; Precision Medicine/methods ; SARS-CoV-2 ; Thrombocytopenia/pathology ; Thrombosis/pathology ; von Willebrand Factor/metabolism
    Chemical Substances Fibrin Fibrinogen Degradation Products ; P-Selectin ; SELP protein, human ; fibrin fragment D ; von Willebrand Factor
    Keywords covid19
    Language English
    Publishing date 2020-07-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms21145168
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes

    Grobler, Corlia / Maphumulo, Siphosethu C / Grobbelaar, L Mireille / Bredenkamp, Jhade C / Laubscher, Gert J / Lourens, Petrus J / Steenkamp, Janami / Kell, Douglas B / Pretorius, Etheresia

    Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), also known as coronavirus disease 2019 (COVID-19)-induced infection, is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia or ... ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), also known as coronavirus disease 2019 (COVID-19)-induced infection, is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia or hypercoagulation and thrombosis. Thrombotic and bleeding or thrombotic pathologies are significant accompaniments to acute respiratory syndrome and lung complications in COVID-19. Thrombotic events and bleeding often occur in subjects with weak constitutions, multiple risk factors and comorbidities. Of particular interest are the various circulating inflammatory coagulation biomarkers involved directly in clotting, with specific focus on fibrin(ogen), D-dimer, P-selectin and von Willebrand Factor (VWF). Central to the activity of these biomarkers are their receptors and signalling pathways on endothelial cells, platelets and erythrocytes. In this review, we discuss vascular implications of COVID-19 and relate this to circulating biomarker, endothelial, erythrocyte and platelet dysfunction. During the progression of the disease, these markers may either be within healthy levels, upregulated or eventually depleted. Most significant is that patients need to be treated early in the disease progression, when high levels of VWF, P-selectin and fibrinogen are present, with normal or slightly increased levels of D-dimer (however, D-dimer levels will rapidly increase as the disease progresses). Progression to VWF and fibrinogen depletion with high D-dimer levels and even higher P-selectin levels, followed by the cytokine storm, will be indicative of a poor prognosis. We conclude by looking at point-of-care devices and methodologies in COVID-19 management and suggest that a personalized medicine approach should be considered in the treatment of patients.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #670475
    Database COVID19

    Kategorien

  3. Article ; Online: Covid-19

    Grobler, Corlia / Maphumulo, Siphosethu C. / Grobbelaar, L. Mireille / Bredenkamp, Jhade C. / Laubscher, Gert J. / Lourens, Petrus J. / Steenkamp, Janami / Kell, Douglas B. / Pretorius, Etheresia

    the rollercoaster of fibrin(ogen), D-dimer, Von Willebrand Factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes

    2020  

    Abstract: CITATION: Grobler, C. et al. 2020. Covid-19 : the rollercoaster of fibrin(ogen), D-dimer, Von Willebrand Factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. International Journal of Molecular Sciences, 21(14): ... ...

    Abstract CITATION: Grobler, C. et al. 2020. Covid-19 : the rollercoaster of fibrin(ogen), D-dimer, Von Willebrand Factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. International Journal of Molecular Sciences, 21(14):5168, doi:10.3390/ijms21145168.

    The original publication is available at https://www.mdpi.com

    Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), also known as coronavirus disease 2019 (COVID-19)-induced infection, is strongly associated with various coagulopathies that may result in either bleeding and thrombocytopenia or hypercoagulation and thrombosis. Thrombotic and bleeding or thrombotic pathologies are significant accompaniments to acute respiratory syndrome and lung complications in COVID-19. Thrombotic events and bleeding often occur in subjects with weak constitutions, multiple risk factors and comorbidities. Of particular interest are the various circulating inflammatory coagulation biomarkers involved directly in clotting, with specific focus on fibrin(ogen), D-dimer, P-selectin and von Willebrand Factor (VWF). Central to the activity of these biomarkers are their receptors and signalling pathways on endothelial cells, platelets and erythrocytes. In this review, we discuss vascular implications of COVID-19 and relate this to circulating biomarker, endothelial, erythrocyte and platelet dysfunction. During the progression of the disease, these markers may either be within healthy levels, upregulated or eventually depleted. Most significant is that patients need to be treated early in the disease progression, when high levels of VWF, P-selectin and fibrinogen are present, with normal or slightly increased levels of D-dimer (however, D-dimer levels will rapidly increase as the disease progresses). Progression to VWF and fibrinogen depletion with high D-dimer levels and even higher P-selectin levels, followed by the cytokine storm, will be indicative of a poor prognosis. We conclude by looking at point-of-care devices and methodologies in COVID-19 management and suggest that a personalized medicine approach should be considered in the treatment of patients.

    Medical Research Council of South Africa (MRC), grant number A0X331

    Self-initiated research and by The Novo Nordisk Foundation, grant number: NNF10CC1016517

    https://www.mdpi.com/1422-0067/21/14/5168

    Publisher's version
    Keywords COVID-19 (Disease) ; Thrombocytopenia ; Blood -- Coagulation ; Thrombosis ; covid19
    Subject code 610
    Language English
    Publishing date 2020-07-21
    Publisher MDPI
    Publishing country za
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top